• Profile
Close

Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin

Cardiovascular Therapeutics Oct 26, 2017

Fazio S, et al. - Bococizumab was tested for LDL-C lowering efficacy, safety, and tolerability in primary hypercholesterolemia patients. For this purpose, two multiple-dose phase II studies were conducted that yielded findings demonstrating safety as well as efficacy of bococizumab in lowering LDL-C in hypercholesterolemic subjects on high doses of statin.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay